Free

Converting IP to $$$ for healthtech/medtech companies (Part 2 of 2)

Actions and Detail Panel

Free

Event Information

Share this event

Date and Time

Location

Location

Online Event

Event description
The Forge presents a two-part, interactive workshop featuring U.S.-based Knobbe Martens and Ontario-based, Epineuron.

About this Event


		Converting IP to $$$ for healthtech/medtech companies  (Part 2 of 2) image

March 11th (1PM-3PM ET)

Part 2 of 2: Converting IP to $$$ for healthtech/medtech companies

This session is a continuation of our first workshop on IP strategy for healthtech/medtech companies (held on February 4, 2021). We will discuss what investors are looking for in respect to IP, the due diligence process, some common pitfalls to avoid, and how to set yourself up for investment success. Like part one, we will have Mike and Sergio from Epineuron present to help illustrate points being made by Ted and Michael from Knobbe Martens.

NOTE: Participants are welcome to join the second session, without attending the first session of the workshop series. This workshop is scheduled for two hours. The first hour will cover the topics discussed below; the final hour will be for questions. Lawyers from Knobbe Martens and founders from Epineuron will make themselves available for companies interested in speaking with them. We will use breakout rooms for this part of the session.

Topics:

- Due diligence

- The process

- What are investors looking for and how to prepare yourself

- Red flags for investors / avoiding pitfalls

- How to meet medtech investors


		Converting IP to $$$ for healthtech/medtech companies  (Part 2 of 2) image

Speakers:

Michael Christensen , Partner, Knobbe Martens

Mr. Christensen is a patent attorney with over 12 years of experience. While he has helped clients protect a variety of technologies, Mr. Christensen focuses on building patent portfolios for startup medical device clients in the ophthalmic, cardiovascular, spine, diabetes, and general neuromodulation fields. Mr. Christensen also has extensive experience conducting patent due diligence for leading Venture Capital firms and other investors. He has also performed several IP audits to help companies identify ways to improve their patent portfolios. One of Mr. Christensen’s areas of expertise is developing strategies for expediting patent prosecution both in the United States and abroad.

Theodore Papagiannis, Partner, Knobbe Martens

Theodore Papagiannis advises companies on developing comprehensive intellectual property portfolios and strategies, especially early-stage medical device companies and other start-ups. Theodore also conducts strategic IP evaluations on behalf of venture capital firms, other investors and other entities in connection with an investment round or acquisition. Mr. Papagiannis has extensive experience in strategically growing IP portfolios in the medical device arena, including in the fields of spine and other orthopedics, injection systems, cardiac and cardiovascular technologies (e.g., for the treatment of atrial fibrillation and other arrhythmias, hypertension, etc.), denervation and neuromodulation, hypertension, tissue ablation, catheters, sheaths and other intravascular technologies and skin treatment. He also has experience with negotiating licenses and other agreements to enhance IP portfolios on behalf of clients. Theodore is currently a member of the board of directors of Sustain SoCal, an organization that accelerates sustainability in Southern California through innovation, collaboration and education, and has been involved in leadership roles with the organization since its inception in 2010. He has unique technical and IP experience in clean and building technologies, including water and wastewater treatment, desalination, recycling and waste management, lighting, clean energy and the like. Prior to beginning his legal career, Theodore worked as an engineer for nearly a decade. He is a licensed Professional Engineer in the State of California.

About Knobbe Martens :

Consistently ranked among the top intellectual property firms in the nation and worldwide, Knobbe Martens has close to 275 lawyers and scientists nationwide and dedicates its practice to all aspects of intellectual property and technology law, including litigation. Knobbe Martens serves a diverse group of clients from multinational corporations to emerging businesses of all stages. The firm is headquartered in Orange County, California, with offices in Los Angeles, New York, San Diego, San Francisco, Seattle and Washington, D.C., and enjoys an international reputation for excellence.

Sergio Aguirre, MBA, Chief Executive Officer

Mr. Aguirre has 10 years of experience in health technology startups both in funding, device development and commercialization. He previously worked in business development roles at the Ontario Centres of Excellence and Centre for Imaging Technology Commercialization. Sergio obtained his MBA from Western University (Ivey School of Business). He also holds a MASc in Biomedical Engineering from McMaster University and a BSc in Biological Science from the University of Guelph.

Dr. Mike Willand, PhD, Chief Technology Officer

Dr. Willand is an expert in the application of bioelectronic medicine to treat denervated muscle and injured nerves. He has over 10 years of experience in researching various therapies to enhance recovery following peripheral nerve injury. Mike obtained his PhD and MASc degree in Biomedical Engineering from McMaster University and a BEng in Electrical and Biomedical Engineering also from McMaster University. He has completed post-doctoral training in Neurosciences and Plastic Surgery at the Hospital for Sick Children.

About Epineuron:

Epineuron is a clinical stage bioelectronic medicine company developing the world’s first device to supercharge nerve regeneration. Their device merges innovations in neuroscience and surgical procedures to deliver regenerative therapy to damaged peripheral nerves, ultimately helping patients regain the functions they have lost. Their lead product, the Nerve Bandage™, has been designated a Breakthrough Device by the FDA in recognition of the impact our technology can have in improving patient outcomes.

Share with friends

Date and Time

Location

Online Event

Save This Event

Event Saved